Know when Premera Bluecross releases new policies or updates existing guidance.
Defines medical necessity, management (pharmacy vs medical benefit), coding, and documentation requirements for denosumab products for osteoporosis, prevention of skeletal-related events, hypercalcemia of malignancy, and giant cell tumor of bone; applies to Premera Blue Cross providers and members.
Policy Summary
PayerPremera Bluecross
PolicyDenosumab Products (coverage and authorization)
Policy CodePolicy N/A
Change TypeMaterial clinical and operational updates
Effective DateAug 7, 202617d
Last ReviewApr 14, 2026
Next Review DateN/A
Key ActionObtain prior authorization and document trials of required preferred biosimilars or two generic bisphosphonates (as specified) to support coverage.
Preferred and non-preferred designations for many denosumab products were updated and prior authorization criteria were changed to require inadequate response or intolerance to specified preferred products.
Dose limit for prevention of skeletal-related events in multiple myeloma and bone metastases was added: 120 mg every 4 weeks.
New HCPCS codes Q5161 and Q5162 were added to the coding section effective April 1, 2026.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
Covered when ALL of the following are met for first-line osteoporosis use with Bildyos/Enoby:
Osteoporosis indication and prior therapy: Treatment of osteoporosis when the individual has tried and had an inadequate response or intolerance to 2 generic bisphosphonates (either 2 oral medications or 1 oral medication and 1 IV medication) unless bisphosphonates are contraindicated2 failed generic bisphosphonates
Oral bisphosphonates considered contraindicated in esophageal disorders (e.g., achalasia, esophageal stricture, Barrett's)
Alternative indications: To increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer OR to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer
Examples of ADT and aromatase inhibitors listed in policy
Dose limitation: Dose is limited to 60 mg every 6 months60 mg q6 months
Bone mass preservation in ADT or aromatase inhibitor therapy
Covered when ALL of the following are met for increasing bone mass in men on androgen deprivation therapy or women on adjuvant aromatase inhibitor therapy:
Indication: To increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer OR to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer
Examples of ADT/anastrozole/exemestane/letrozole listed in policy
Dose limitation: Dose is limited to 60 mg every 6 months60 mg q6 months
Prevention of skeletal-related events — first-line oncology denosumab
Covered when ALL of the following are met for oncology indications with Bilprevda/Xtrenbo (first-line oncology denosumab products):
Indications: Prevention of skeletal-related events in multiple myeloma OR prevention of skeletal-related events in individuals with bone metastases from solid tumors (for breast cancer: expected survival >= 3 months; for prostate cancer: castration recurrent disease)
Prior zoledronic acid trial: Documented inadequate response or intolerance to intravenous 4 mg zoledronic acidfailed IV zoledronic acid
Dose limitation: Dose is limited to 120 mg every 4 weeks120 mg q4 weeks
Prevention of skeletal-related events — second-line oncology denosumab
Covered when ALL of the following are met for second-line oncology denosumab products:
Prior product trials: The individual has tried and had an inadequate response or intolerance to Bilprevda (denosumab-nxxp) AND Xtrenbo (denosumab-qbde)failed first-line denosumab brands
Prior zoledronic acid trial: Documented inadequate response or intolerance to intravenous 4 mg zoledronic acidfailed IV zoledronic acid
Dose limitation: Dose limited to 120 mg every 4 weeks120 mg q4 weeks
Hypercalcemia of malignancy
Covered when ALL of the following are met for hypercalcemia of malignancy:
Zoledronic acid failure: Documented inadequate response or intolerance to intravenous 4 mg zoledronic acidfailed IV zoledronic acid
For second-line products, also require failure of Bilprevda and Xtrenbo where specified
Giant cell tumor of bone
Covered when ALL of the following are met for giant cell tumor of bone:
Prior denosumab trial: The individual has tried and had an inadequate response or intolerance to Bilprevda (denosumab-nxxp) AND Xtrenbo (denosumab-qbde) before second-line agentsfailed first-line denosumab brands
Applies to second-line denosumab products
Covered Indications (selected)
Covered when consistent with FDA‑approved indications and guideline-supported uses, including but not limited to:
Indications with demonstrated benefit: Postmenopausal women at high risk for fracture (reduced vertebral, nonvertebral, and hip fractures); men on androgen deprivation therapy for nonmetastatic prostate cancer to increase BMD and reduce vertebral fractures; individuals with glucocorticoid-induced osteoporosis to increase BMD; women on aromatase inhibitors to increase BMD and reduce clinical fractures; prevention of skeletal-related events in patients with bone metastases or multiple myeloma (Xgeva non-inferior to zoledronic acid)FDA-approved age limits and indication-specific dosing per labeling
See dosing limit for SRE prevention (120 mg every 4 weeks) where applicable.
All uses of denosumab products that are not specifically listed as covered indications in this policy are considered investigational. The policy lists the denosumab products for which coverage criteria are provided; requests for products or indications not described in the coverage sections should be treated as investigational and require appropriate justification or will be denied.
Available randomized evidence for denosumab in men with osteoporosis is limited. A systematic review identified two placebo‑controlled studies in men; neither study demonstrated a statistically significant reduction in vertebral fracture risk with denosumab. Because of the small evidence base and lack of demonstrated benefit for this outcome, coverage for denosumab specifically to reduce vertebral fracture risk in men is limited by the evidence.
The evidence does not demonstrate that denosumab provides a statistically significant reduction in vertebral fracture risk when used solely for that outcome in men with osteoporosis. Requests for denosumab intended only to reduce vertebral fractures in men should be evaluated in light of the limited trial data and may be considered not medically necessary when no other guideline‑supported indication or rationale is present.
Osteoporosis dosing60 mg subcutaneously every 6 months
Oncology / SRE dosing120 mg subcutaneously every 4 weeks
Quantity limit (policy)Dose limited per indication: 60 mg q6 months for osteoporosis; 120 mg q4 weeks for SRE prevention
SRE prevention dosing
Standard SRE prevention dose120 mg subcutaneously every 4 weeks
Applies toPrevention of skeletal-related events in multiple myeloma and bone metastases from solid tumors
Provider Actions and Authorization Requirements
Prior Authorization
Prior Authorization Required for Non‑Preferred Denosumab
Prior authorization required for non-preferred denosumab products. Prior authorization must be obtained before coverage will be provided for non-preferred denosumab products listed in the policy.
Authorization duration: up to 12 months for non-formulary exception reviews when condition stabilized or improved; otherwise see re-authorization durations in policy (some products approved up to 2 years).
Step Therapy
Step Therapy — Trial of Preferred Products Required
Step therapy — failure to trial preferred biosimilars required. Prior authorization for non-preferred denosumab products requires documentation of an inadequate response or intolerance to the preferred denosumab products or preferred biosimilars as specified in the policy.
For non-preferred group including Boncresa, Bosaya, Conexxence, Jubbonti, Ospomyv, Osvyrti, Prolia, and Stoboclo: must have tried and had an inadequate response or intolerance to Bildyos (denosumab-nxxp) AND Enoby (denosumab-qbde).
Background
Denosumab products are monoclonal antibodies that inhibit the RANK ligand pathway and are included in this policy across multiple brands and biosimilars. The policy lists numerous denosumab preparations (including branded products such as Prolia and Xgeva and multiple biosimilars and newly coded products) and aligns coverage to indication‑specific criteria, dosing limits, and prior‑therapy requirements. Providers should refer to the policy’s product list and the associated criteria when requesting coverage because management (pharmacy vs medical benefit), dosing thresholds, and required documentation vary by product.
Mechanism summaryInhibits RANKL to reduce osteoclast-mediated bone resorption
Clinical uses notedUsed for osteoporosis, prevention of skeletal-related events, hypercalcemia of malignancy, and giant cell tumor of bone
Generic bisphosphonates
Included agentsAlendronate (oral), Ibandronate (oral), Risedronate (oral), Zoledronic acid (IV)
Role in step therapyTrial of two generic bisphosphonates (two oral or one oral + one IV) required for osteoporosis prior to first-line denosumab unless contraindicated
Initial Therapy Criteria
Initial therapy — Bildyos (denosumab-nxxp) and Enoby (denosumab-qbde)
Initial therapy criteria for first-line products
Osteoporosis initial criteria: Bildyos (denosumab-nxxp) and Enoby (denosumab-qbde) may be considered medically necessary for osteoporosis after inadequate response or intolerance to 2 generic bisphosphonates (2 oral or 1 oral + 1 IV) unless contraindicated2 failed generic bisphosphonates
Dose 60 mg every 6 months
Initial therapy — Bilprevda (denosumab-nxxp) and Xtrenbo (denosumab-qbde)
Initial therapy criteria for oncology first-line products
Oncology initial criteria: Bilprevda (denosumab-nxxp) and Xtrenbo (denosumab-qbde) may be considered medically necessary for prevention of skeletal-related events with documented inadequate response or intolerance to IV 4 mg zoledronic acid and oncology-specific survival/castration requirements where applicable
Re-authorization and Continuation Criteria
Re-authorization
Re-authorization conditions and durations
Stability and side effects: May be re-approved when documentation shows condition has stabilized or improved and individual has not experienced serious or intolerable side effectsclinical improvement/stability
Duration varies by product (12 months common; up to 2 years for selected products)
Continuation and transition guidance
Recommendations on duration and transitions after stopping therapy
Post-denosumab discontinuation: If denosumab therapy is discontinued, individuals should be transitioned to another antiresorptive to mitigate rebound bone lossas clinically appropriate
AACE/ACE: no holiday recommended for non-bisphosphonate antiresorptives; continue as long as clinically appropriate
Step Therapy Requirements
Requirement
Details
Prior trial(s) as listed per indication
Osteoporosis: trial and inadequate response or intolerance to 2 generic bisphosphonates (either 2 oral agents or 1 oral + 1 IV) unless bisphosphonates are contraindicated; dose limited to 60 mg every 6 months.
Increase bone mass with ADT or aromatase inhibitor therapy: indication for men on androgen deprivation therapy or women on adjuvant aromatase inhibitor therapy; dose limited to 60 mg every 6 months.
Prevention of skeletal-related events (first-line oncology): documented inadequate response or intolerance to IV 4 mg zoledronic acid required; dose limited to 120 mg every 4 weeks.
Prevention of skeletal-related events (second-line oncology) and certain second-line uses: trial and inadequate response or intolerance to Bilprevda (denosumab-nxxp) AND Xtrenbo (denosumab-qbde) AND documented inadequate response or intolerance to IV 4 mg zoledronic acid; dose limited to 120 mg every 4 weeks.
Hypercalcemia of malignancy and giant cell tumor of bone (for listed products): documented inadequate response or intolerance to IV 4 mg zoledronic acid; for some products also require prior inadequate response or intolerance to Bilprevda AND Xtrenbo.
Requirement
Preferred product trial requirement
Step therapy for many non-preferred denosumab products
Must have tried and had an inadequate response or intolerance to Bildyos (denosumab-nxxp) AND Enoby (denosumab-qbde) before approval of many non-preferred denosumab agents.
For another set of non-preferred agents, must have tried and had an inadequate response or intolerance to Bilprevda (denosumab-nxxp) AND Xtrenbo (denosumab-qbde) before coverage.
These preferred/non-preferred designations and the required trials were implemented in the 2026 update to the policy.
Dose for SRE prevention120 mg subcutaneously every 4 weeks (policy dose limitation)
Site of Care and Benefit Management
Billing Rule
Confirm medical vs pharmacy benefit for denosumab products
Some denosumab products are managed through the medical benefit and are administered subcutaneously by a healthcare professional; verify benefit management (medical vs pharmacy) and bill under the appropriate benefit.
Bildyos, Enoby and several others are administered subcutaneously and may be managed through either medical or pharmacy benefit.
Bilprevda, Xtrenbo, Xgeva and others are managed through the medical benefit.
Note
Administer subcutaneously per benefit/site‑of‑care guidance
Administer denosumab subcutaneously in the setting consistent with member benefits and site‑of‑care guidance (office, infusion center, or home) and bill according to the applicable benefit and setting.
Biosimilar Products and Preferred Agents
Billing Rule
Product‑specific coding: Prolia/Xgeva and biosimilars
Prolia/Xgeva and biosimilar denosumab products have specific HCPCS/Q‑code assignments; follow the policy’s coding table when billing and apply product‑specific management per the policy.
Multiple Q‑codes correspond to biosimilar denosumab products; use the code listed in the policy.
Billing Rule
Preferred biosimilars and their Q‑codes
Designated preferred biosimilars include Q5136 and Q5157–Q5162 as listed in the coding section and the policy; many non‑preferred denosumab agents require documented inadequate response or intolerance to the preferred products prior to approval.
Q5136, Q5157–Q5162 are assigned to biosimilar denosumab products in the Coding section.
Policy change designated Bildyos, Enoby, Bilprevda and Xtrenbo as preferred products; verify required trials per product group.
Policy Summary
PayerPremera Bluecross
PolicyDenosumab Products (coverage and authorization)
Policy CodePolicy N/A
Change TypeMaterial clinical and operational updates
Effective DateAug 7, 202617d
Last ReviewApr 14, 2026
Next Review DateN/A
Key ActionObtain prior authorization and document trials of required preferred biosimilars or two generic bisphosphonates (as specified) to support coverage.
Dose limit of 120 mg every 4 weeks added in 2026 update
For non-preferred group including Aukelso, Bomyntra, Jubereq, Osenvelt, Oziltus, Wyost, Xbryk, and Xgeva: must have tried and had an inadequate response or intolerance to Bilprevda (denosumab-nxxp) AND Xtrenbo (denosumab-qbde).
Preferred denosumab products (preferred biosimilars) include Bildyos (denosumab-nxxp), Enoby (denosumab-qbde), Bilprevda (denosumab-nxxp), and Xtrenbo (denosumab-qbde) per 2026 update.
Documentation Required
Documentation Requirements for Authorization
Required medical record documentation. Medical records submitted must document that the medical necessity criteria are met and should include diagnosis, medication history, and supporting clinical rationale.
Office visit notes containing the diagnosis and medication history.
Documentation of trials and outcomes (e.g., dates, doses, reason for discontinuation) showing inadequate response or intolerance to required preferred denosumab products or to the specified number/type of bisphosphonates when applicable.
If bisphosphonate therapy is contraindicated, documentation of the contraindication (e.g., esophageal disorders) is required.
For non-formulary exception reviews, documentation that the condition has stabilized or improved and absence of serious or intolerable side effects when requesting approval up to 12 months.
Billing Rule
Coding Documentation and Billing Rules
Coding and billing documentation. Ensure correct HCPCS/CPT/NDC coding and include product name (brand and manufacturer) and HCPCS when submitting claims; include supporting documentation with J-code usage where applicable.
Policy references HCPCS code J3590 with parenthetical listing of certain denosumab products on historical updates; new HCPCS codes Q5161 and Q5162 were added effective April 1, 2026 — verify correct code for the specific product and administration.
Include the specific denosumab product name (e.g., Bildyos, Enoby, Prolia, Xgeva) on the claim and in supporting documentation to align with preferred vs non-preferred product determinations.
When billing under miscellaneous J-codes (e.g., J3590), include manufacturer/product name as a parenthetical per historical policy guidance to facilitate adjudication.
Denial Risk
Denial Risk for Missing or Nonconforming Documentation
Denial risk — nonconforming indication or missing prior therapy. Requests lacking required prior trials of preferred agents, missing documentation of intolerance/ inadequate response, or insufficient medical record evidence are at high risk for denial.
If prior therapy requirements (preferred denosumab trials or bisphosphonate trials) are not clearly documented, the request may be denied.
Nonconforming indications (use outside the policy-listed indications) without supporting clinical justification may be denied.
Oral bisphosphonate contraindication
Oral bisphosphonates considered contraindicated in individuals with esophageal disorders (e.g., achalasia, esophageal stricture, Barrett's)
Osteoporosis definition
DefinitionA pathological condition characterized by bone fragility and increased risk of fracture
MeasurementOften measured by low bone mineral density (BMD); T-score ≤ -1.0 indicates low bone mass/osteoporosis risk
Clinical goalTherapy aims to prevent fractures by reducing bone loss and improving BMD
failed IV zoledronic acid
Dose 120 mg every 4 weeks
Initial therapy guidance
Guideline-based initial therapy recommendations
Initial therapy options: Guidelines recommend alendronate, risedronate, zoledronic acid, or denosumab as appropriate initial therapies for many individuals with osteoporosis; anabolic and other agents (abaloparatide, teriparatide, romosozumab, denosumab) may be considered for those unable to use oral therapy or at very high fracture riskper guideline specifics
Follow AACE/ACE and ACP guidance for duration and sequencing
Prior therapy requirement
Documented inadequate response or intolerance to IV 4 mg zoledronic acid required for SRE indication
Hypercalcemia / giant cell tumor useMay be considered medically necessary for hypercalcemia of malignancy and giant cell tumor of bone when there is inadequate response or intolerance to IV 4 mg zoledronic acid and prior trial of Bilprevda AND Xtrenbo for some products
SRE prevention dosing notedFor relevant oncology indications, dose limited to 120 mg every 4 weeks
Refer to the member’s benefit plan for site‑of‑care coverage and billing requirements.
Denosumab is administered subcutaneously; setting is at provider discretion within benefit allowances.
Step Therapy
Required preferred pair (Bilprevda + Xtrenbo) for another subgroup
For a subset of non‑preferred agents, the policy requires documented inadequate response or intolerance to a specific preferred pair (Bilprevda AND Xtrenbo) before second‑group non‑preferred agents will be considered medically necessary.
Policy update specifies Bilprevda (denosumab-nxxp) AND Xtrenbo (denosumab-qbde) as the required preferred pair for a second subgroup.
Provide documentation of inadequate response or intolerance to both agents to support approval.